CA Patent

CA3232602A1 — An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis

Assigned to Cosmo Technologies Ltd · Expires 2023-04-13 · 3y expired

What this patent protects

The present disclosure relates to an (in situ gelling) enema containing Rifamycin SV and its use in the treatment of pouchitis, proctitis and/or distal ulcerative colitis (including proctosigmoiditis). More particularly, the present disclosure describes an in situ gelling retenti…

USPTO Abstract

The present disclosure relates to an (in situ gelling) enema containing Rifamycin SV and its use in the treatment of pouchitis, proctitis and/or distal ulcerative colitis (including proctosigmoiditis). More particularly, the present disclosure describes an in situ gelling retentive enema containing Rifamycin SV for treating, ameliorating, reducing the severity of or slowing the progression of pouchitis, proctitis and/or distal ulcerative colitis (including proctosigmoiditis).

Drugs covered by this patent

Patent Metadata

Patent number
CA3232602A1
Jurisdiction
CA
Classification
—
Expires
2023-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Cosmo Technologies Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.